Shionogi to Acquire IntraBio for $2 Billion, Expanding Rare Disease…

Event summary

Shionogi to acquire IntraBio for $2 billion, adding AQNEURSA® to its rare disease portfolio.
AQNEURSA® approved for Niemann-Pick disease Type C and Ataxia-Telangiectasia in the U.S. and EU.
Transaction expected to close between November and December 2026, subject to regulatory approvals.
IntraBio's expertise to strengthen Shionogi's rare disease pipeline, including Pompe disease and Fragile X syndrome.

The big picture

Shionogi's acquisition of IntraBio marks a significant step in its strategy to become a leading player in the rare disease space. The deal follows Shionogi's acquisition of global rights to edaravone (RADICAVA®) earlier in 2026, demonstrating its commitment to addressing unmet medical needs in neurological and rare diseases. The $2 billion transaction underscores the growing focus on rare disease therapies, driven by high unmet needs and the potential for significant market growth.

What we're watching

Integration Challenges: How Shionogi will integrate IntraBio's capabilities and portfolio into its existing rare disease business.
Regulatory Approvals: The pace at which the transaction receives necessary regulatory approvals and closes.
Pipeline Development: Whether the acquisition accelerates Shionogi's development of new treatment options for rare diseases.